Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
  • Journal club
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
  • Journal club
  • Alerts
  • Subscriptions

Idiopathic pulmonary fibrosis and lung cancer: future directions and challenges

Ahmad Abu Qubo, Jamil Numan, Juan Snijder, Maria Padilla, John H.M. Austin, Kathleen M. Capaccione, Monica Pernia, Jean Bustamante, Timothy O'Connor, Mary M. Salvatore
Breathe 2022 18: 220147; DOI: 10.1183/20734735.0147-2022
Ahmad Abu Qubo
1Department of Pathology, Faculty of Medicine, Hashemite University, Zarqa, Jordan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ahmad Abu Qubo
Jamil Numan
2Department of Radiology, Columbia University Medical Center, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juan Snijder
3Department of Pediatrics, Einstein Medical Center, Philadelphia, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Padilla
4Department of Pulmonary Medicine, Mount Sinai, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John H.M. Austin
2Department of Radiology, Columbia University Medical Center, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathleen M. Capaccione
2Department of Radiology, Columbia University Medical Center, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kathleen M. Capaccione
Monica Pernia
5Department of Medicine, Metropolitan Hospital, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean Bustamante
6Department of Oncology, West Virginia University, Morgantown, WV, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy O'Connor
2Department of Radiology, Columbia University Medical Center, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary M. Salvatore
2Department of Radiology, Columbia University Medical Center, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ms5680@cumc.columbia.edu
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive disease of pulmonary scarring. New treatments slow disease progression and allow pulmonary fibrosis patients to live longer. Persistent pulmonary fibrosis increases a patient's risk of developing lung cancer. Lung cancer in patients with IPF differs from cancers that develop in the non-fibrotic lung. Peripherally located adenocarcinoma is the most frequent cell type in smokers who develop lung cancer, while squamous cell carcinoma is the most frequent in pulmonary fibrosis. Increased fibroblast foci in IPF are associated with more aggressive cancer behaviour and shorter doubling times. Treatment of lung cancer in fibrosis is challenging because of the risk of inducing an exacerbation of fibrosis.

In order to improve patient outcomes, modifications of current lung cancer screening guidelines in patients with pulmonary fibrosis will be necessary to avoid delays in treatment. 2-fluoro-2-deoxy-d-glucose (FDG) positron emission tomography (PET) computed tomography (CT) imaging can help identify cancer earlier and more reliably than CT alone. Increased use of wedge resections, proton therapy and immunotherapy may increase survival by decreasing the risk of exacerbation, but further research will be necessary.

Abstract

Pulmonary fibrosis fulfils the criteria of precancer set forth by the US National Cancer Institute https://bit.ly/3QXIuK4

Introduction

Pulmonary fibrosis is scarring of the lung parenchyma that causes difficulty breathing. It is occurring more frequently as the population is living longer [1]. Fibrosis is even more devastating because it is associated with an increased risk for lung cancer [2]. A large Korean population study reported that 1.2% of the overall population developed lung cancer; however, the percentage increased to 5% in patients with emphysema and to nearly 6% in those with fibrosis. Moreover, in patients who had emphysema and fibrosis combined, the risk of lung cancer increased to 12% [3]. Smoking alone could not explain why Ozawa et al. [4] found the cumulative incidence of lung cancer to be 15% and 55% when Japanese patients lived with IPF for 5 years and 10 years, respectively. Yoon et al. [5] showed a nearly five-fold increased rate of lung cancer in those with an autoimmune disease but were unsure if it was attributable to fibrosis or immunosuppression. With the cumulative risk of cancer in these patients increasing over time, and with more pulmonary fibrosis patients living longer, owing to the new approved anti-fibrotic treatments, the percentage of these patients developing lung cancers is expected to increase [6–8].

The prevalence of lung cancer in pulmonary fibrosis patients ranges from 4.4% to 13%, but is as high as 48% in autopsy studies [9–13]. Even the earliest findings of pulmonary fibrosis, called interstitial lung abnormalities, increased the risk of cancer in the National Lung Screening Trial, with an adjusted incidence rate ratio of 1.33 [14]. Lung cancer in idiopathic pulmonary fibrosis (IPF) patients is linked to a worse prognosis and decreased survival [5, 15, 16]. Also, patients with IPF who have had a single lung transplantation have over 20 times increased risk of developing lung cancer compared to the general population [17]. In a retrospective study by Brett et al. [18] in 900 patients with a lung cancer diagnosis, one in three patients were found to have pulmonary fibrosis.

Why does lung cancer occur in pulmonary fibrosis?

Fibrosis is a condition inherently related to relentless transforming growth factor (TGF)-β action that regulates many intracellular mediators and pathways recognised in the oncology literature, including cell growth, organ development, the immune system, metastasis and progression of cancer [19]. TGF-β promotes cellular growth in cancer cells, and has the opposite effect in benign cells, a phenomenon coined the “TGF-β paradox” [19]. Zhang et al. [19] proposed that the TGF-β paradox is due to extracellular signal-regulated kinase (ERK) pathway activation in malignant cells and inactivation in non-cancer cells. Benign cells activate their proliferation cycle via ERK upregulation after TGF-β stimulation, in the same way as their oncogenic counterpart, but respond to homeostatic mechanisms or autoregulation [20]. In healthy cells, when natural TGF-β receptors (types I and II) are abundant and activated by TGF-β, there is a downstream activation of ERK proteins and co-activation of protein phosphatase 2A-α, which acts as an intrinsic safety control [21]. Downregulation of TGF-β receptors is the pivotal event that changes cellular behaviour. Low TGF-β receptor levels promote metastasis and cancer progression and are crucial for early carcinogenesis [20]. Pirfenidone inhibits TGF-β, preventing the activation of downstream signalling pathways that lead to the production of collagen and other extracellular matrix (ECM) proteins [22]. In a study of patients with IPF, researchers found that those with shorter telomeres had a faster rate of lung function decline than those with longer telomeres [23]. This suggests that telomere biology may play a role in the development and progression of IPF [23].

Programmed cell death-ligand 1 (PD-L1) expression is increased in IPF and lung cancer [24]. PD-L1 is a protein that is expressed on the cell's surface and binds to the PD1 receptor on T-cells [25]. This interaction leads to the suppression of the immune response, which contributes to the pathogenesis of these diseases [24]. The MET signalling pathway (a receptor tyrosine kinase whose ligand is hepatocyte growth factor) is a major regulator of cell growth and proliferation and is activated in both IPF and lung cancer in response to hypoxia [2, 26]. Its activation in different cancers leads to increased cell proliferation and tumour growth and increased expression of a number of genes involved in cell proliferation [27]. In addition, the MET signalling pathway activates the Akt signalling pathway (a serine-threonine protein kinase), which results in increased growth and promotion of cell survival [28, 29]. In IPF, the MET signalling pathway is upregulated in fibroblasts and myofibroblasts that are responsible for the excessive collagen deposition and tissue fibrosis that characterises the disease [30].

Pulmonary fibrosis provides a microenvironment where cancer can thrive [15]. Lung cancer in pulmonary fibrosis patients is more aggressive. The reason behind this is multifactorial. TGF-β is produced by fibroblasts in pulmonary fibrosis and cancer-derived epithelial cells [31]. It increases myofibroblast employment at the cancer margins, protecting them from apoptosis and allowing them to invade basement membranes [31].

Fibrosis causes the ECM to undergo extensive remodelling, with collagen deposition and fibre degradation. The effect of stiff matrices in cancers is profound [32]. The fibrotic ECM alters mechanotransductive signalling, redefining cell-to-cell communication [33]. The tropism of cancer towards stiffened cells was coined “durotaxis” by Lo et al. [34], for the cellular preference for hardened substrates. A stiff ECM not only provides a two-way communication system between the interstitium and cancer cells [35], but also promotes macrophages and fibroblasts to undergo differentiation into their malignant counterparts, known as tumour-associated macrophages and cancer-associated fibroblasts [36, 37]. Epithelial-to-mesenchymal transition (EMT) is a vital process for fibrosis and cancer [38].

Is lung fibrosis a precancerous condition?

The association between pulmonary fibrosis and lung cancer is not a new topic. Papers have been written about this since the 1960s [2, 39, 40]. Hyperplasia and metaplasia seen in IPF may lead to additional transformation and cancer development [41]. Some have proposed that the unrelenting bronchial regeneration may lead to cancer formation [18]. There are vast similarities between fibroblasts in IPF and cancer cells [42]. Both multiply rapidly, evade immune response and growth suppressors, resist apoptosis, have persistent activation of proliferative signalling pathways and utilise the Warburg effect [42, 43]. The Warburg effect refers to increased glucose uptake by malignant cells and fibroblasts of IPF [7, 44]. This glucose is later anaerobically processed, yielding by-products to be used in biosynthesis of molecules needed for the uncontrolled proliferation of cells [44]. Fibroblasts in IPF differ from normal lung fibroblasts with their ability to disrupt basement membranes [43]. In IPF, TGF-β causes EMT and alveolar epithelial type 2 cells are transformed to myofibroblasts. Activated myofibroblasts secrete ECM including collagen and alpha smooth muscle actin. In lung cancer, cancer-associated fibroblasts are present at the site of tumour initiation and responsible for endothelial–mesenchymal transformation leading to tumour angiogenesis [40]. The National Cancer Institute in the USA defines precancer as conditions meeting five criteria: 1) the condition must have a higher likelihood of cancer, 2) the cancer develops from the precancerous condition, 3) the precancer is distinct from its native tissue, 4) the condition is not cancer but can have some characteristics of cancers, and finally 5) there must be techniques available for the condition to be identified [45]. IPF fulfils the five criteria set forth by the National Cancer Institute and therefore qualifies as a precancerous condition (table 1).

View this table:
  • View inline
  • View popup
TABLE 1

Idiopathic pulmonary fibrosis (IPF) fulfils the five criteria set forth by the National Cancer Institute [45] and therefore qualifies as a precancerous condition

Difference between lung cancers in fibrotic versus non-fibrotic lung

Nonsmall cell lung cancer (NSCLC) is the most prevalent histological type of lung cancer in the overall population. Among NSCLCs, squamous cell carcinoma (SCC) and adenocarcinoma are the most common subtypes. Since 1990, adenocarcinoma has remained the most common histological subtype in men and women irrespective of smoking status [46] Some studies found that the most common subtype of NSCLC found in patients with fibrosis is SCC [47–50].

Most SCCs (60–80%) in non-IPF patients arise in the proximal portions of the tracheobronchial tree. However, in IPF patients, the lesions are mainly peripheral, in the lower lobes, and near areas of honeycombing [51]. Lee et al. [52] published a matched case–control study of surgically treated lung cancer patients with and without pulmonary fibrosis and discovered that patients with IPF plus lung cancer (IPF-LC) were more likely to have a higher ratio of forced expiratory volume in 1 s to forced vital capacity (FVC), lower FVC, lower diffusing capacity of the lung for carbon monoxide and higher carcinoembryonic antigen levels than those with lung cancer only (p<0.01). Post-operative survival was notably lower in patients with IPF-LC than in those with lung cancer only (5-year survival rate 37.5% versus 72.5%, p=0.001). Additionally, IPF-LC patients had worse respiratory outcomes, worse symptoms and higher rates of respiratory deaths and post-operative deaths than non-IPF lung cancer patients (p<0.001) [52]. Furthermore, cancer that occurs in fibrotic lung progresses more rapidly because of the tumour microenvironment, which is less likely to control tumour growth and dissemination [15]. Fibroblast proliferation is related to disease progression [53]. The study by Khan et al. [53] from 2015 showed that most patients with fibrosis and lung cancer had some amount of SCC in their tumours. This is not surprising given that, within pathology specimens of patients with lung cancer and fibrosis, there are atypical epithelial cells adjacent to squamous metaplasia, which is next to carcinoma in situ and invasive SCC, demonstrating evolution of the neoplasm [53]. Due to the distinct features of cancers in pulmonary fibrosis patients and lung cancer in the general population, some have labelled these cancers as “scar-cinoma” [43, 54].

Lung cancer screening in patients with pulmonary fibrosis

The National Comprehensive Cancer Network in the USA considers pulmonary fibrosis a risk factor for lung cancer. Nonetheless, the main indication for a yearly low-dose chest computed tomography (CT) screening remains a strong smoking history (≥20 pack-years) [55]. Tzouvelekis et al. [56] suggested an annual high-resolution CT as a lung cancer screening method for IPF patients and proposed that nodules <8 mm should be followed-up every 3–6 months. Nodules >8 mm should undergo 2-fluoro-2-deoxy-d-glucose (FDG) positron emission tomography (PET)-CT. Patients with imaging findings suggesting a neoplastic lesion should have a minimally invasive biopsy [56]. It should be noted that patients with fibrosis undergoing CT-guided biopsy could be at higher risk of complications from peri-procedural pneumothorax [57]. In addition, pneumothoraces in patients with fibrosis have an increased risk of reoccurring [58].

The low rate of detection of lung cancer among living subjects with pulmonary fibrosis, when compared to post mortem diagnosis, highlights the need for standardised lung cancer screening guidelines for patients with pulmonary fibrosis to allow early detection. If the majority of lung cancers in patients with fibrosis are SCC, which tends to have shorter doubling times than adenocarcinoma, follow-up of nodules identified on chest CT may need modification.

Lung cancer is challenging to detect in fibrotic lung tissue where the leading edge of fibrosis often has a mass-like configuration confounding timely diagnosis. Some cancers in patients with IPF can mimic lung infection, delaying diagnosis (figure 1). FDG PET-CT scanning could be useful for evaluation of fibrotic lung. Low-grade FDG PET-CT uptake occurs in areas of fibrosis, while cancers are distinguished from fibrosis with their very high standardised uptake value (figure 2).

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Evolution over 6 months of mucinous adenocarcinoma in a background of usual interstitial pneumonia on chest computed tomography. The cancer looks like consolidation, making early diagnosis challenging.

FIGURE 2
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2

a) An axial chest computed tomography (CT) image and b) a fused axial 2-fluoro-2-deoxy-d-glucose (FDG) positron emission tomography (PET)-CT image demonstrate peripheral squamous cell cancer occurring in a patient with a “probable usual interstitial pneumonia” pattern. There is low maximum standardised uptake value (SUVmax) in fibrotic lung parenchyma compared to tumour SUVmax of 12.5.

Treatment of lung cancer in patients with pulmonary fibrosis

The lung cancers found in patients with fibrosis are typically early-stage like those found in lung cancer screening, because chest CT scans are frequently performed to evaluate the progression of fibrosis. Early-stage lung cancer in the absence of fibrosis is usually treated with surgery for cure, but surgery may not be possible in those with fibrosis due to respiratory compromise in this population or fear of exacerbation of fibrosis [59]. Therefore, patients with fibrosis and lung cancer may be referred for radiation and chemotherapy more than their counterparts without fibrosis. Treatment of lung cancer in fibrosis patients is complicated: surgery, chemotherapy and radiation can cause exacerbations of fibrosis and increase the likelihood of a poor outcome [60]. Supportive care may offer the same outcomes as traditional treatments in this group of patients. Diminished survival for patients with lung cancer and fibrosis is an opportunity for more effective therapeutic interventions.

Surgery

Surgical excision is the mainstay for treatment of early-stage lung cancer in non-fibrotic patients. Since patients with fibrosis typically have early-stage lung cancer, surgery would seem to be the best option. Lung cancers accompanied with a histopathological diagnosis of IPF carry worse post-operative mortality when compared to lung cancer in non-IPF patients [61]. Saito et al. [62] reported that the 5-year post-operative survival rates were 61.6% in IPF-LC patients with cancer stage IA (≤1.0 cm) and 83.0% in those without IPF (p<0.0001). Multivariate analysis showed that for lung tumours measuring 1.1–2.0 cm, lobectomy and segmentectomy have similar survival rates; however, patients experienced better outcomes with wedge resection, supporting the concept that for lung cancers in fibrosis, smaller surgical procedures are better. For tumours measuring 2.1–3.0 cm, lobectomy remains the standard surgical technique. Nevertheless, for patients in whom lobectomy is not advisable, segmentectomy and wedge resection show comparable survival rates [63]. Any resection will cause a reduction in pulmonary function. Larger procedures cause more complications, including acute exacerbation, acute lung injury/acute respiratory distress syndrome, and higher post-operative mortality [63]. The risk of post-operative exacerbation was less with pirfenidone prior to surgery [64].

Chemotherapy

In the non-IPF NSCLC population, chemotherapy combined with immunotherapy is typically chosen as the main alternative to surgery for those with tumour PD-L1 expression >50%. For patients with squamous cancers, a combination of pembrolizumab (anti-PD-L1 antibody), carboplatin and either paclitaxel or nab-paclitaxel can be used. In NSCLC patients with non-squamous cancer, the currently most used combination consists of carboplatin and pemetrexed with pembrolizumab [65–67].

The use of combined regimens or sole immunotherapy alone has not been broadly tested in IPF-LC patients. Ide et al. [68] reported a case of a 62-year-old patient with adenocarcinoma and IPF who showed a complete response to nivolumab (a BRAF inhibitor) for >1 year without any sign of exacerbation of IPF. Conversely, Yamaguchi et al. [69] recognised pulmonary fibrosis as a significant risk factor for the incidence of drug-induced pneumonitis secondary to pembrolizumab use in patients with NSCLC (p=0.0008).

Watanabe et al. [70] studied the efficacy of chemotherapy on patients with lung cancer and pulmonary fibrosis, specifically in advanced NSCLC-IPF patients. In such a study, a carboplatin and etoposide combination demonstrated mortality benefits in patients with stage III NSCLC-IPF comparable to those obtained in NSCLC patients without IPF. Minegishi et al. [71] studied the effects of carboplatin and etoposide (or paclitaxel) in lung cancer in patients with fibrosis. Lung cancer patients with fibrosis had a similar median progression-free survival rate but worse overall survival rate to lung cancer patients without fibrosis. They reported a small incidence of treatment-related acute exacerbations (5.8%) and a variable rate of toxicities. Nevertheless, most patients tolerated five complete cycles of both drugs.

New clinical trials testing specific monoclonal antibodies and tyrosine kinase inhibitors for the treatment of NSCLCs are in progress. A phase I/II clinical trial studying the efficacy and side-effects of a combination of stereotactic body radiation therapy (SBRT) and an anti-TGF-β antibody (fresolimumab) for patients with NSCLC is underway (ClinicalTrials.gov identifier NCT02581787). Fresolimumab therapy has been shown to decrease the clinical progression of systemic sclerosis [72]. More studies concerning the use of other inhibitors (for ALK, EGFR, ROS1 and BRAF) in patients with pulmonary fibrosis and lung cancer are necessary.

Shared signalling pathways for IPF and lung cancer could be exploited as common targets for the treatment of both. Yamamoto et al. [73] studied the combination of pirfenidone added to immune checkpoint inhibitors or carboplatin-based chemotherapy for the treatment of NSCLC in patients with IPF and found that no patients developed acute exacerbations of their pulmonary fibrosis. Furthermore, cancer-associated fibroblasts promote cancer progression and pirfenidone inhibits fibroblasts and crosstalk between fibroblasts and cancer cells [74]. Nintedanib, a tyrosine kinase inhibitor, has been used successfully in combination with docetaxel for treatment of advanced NSCLC [75].

Radiation therapy

Patients considered unsuitable for surgery may be referred for definitive radiation therapy. SBRT is an effective, noninvasive modality for patients with early-stage NSCLC who cannot endure surgical resection due to comorbidities [76–78]. Only a few studies have outlined the outcomes of SBRT in patients with fibrosis. Yamashita et al. [79] demonstrated that SBRT caused severe pulmonary toxicity in nine out of 13 patients with IPF, and seven of these cases were fatal. Pulmonary toxicity is one of the most prevalent complications after radiation therapy for the treatment of lung cancer. Severe pulmonary toxicity arises in 1.5–20% of patients who receive SBRT and in 5.0–25% of those who receive standard fractionated radiation therapy [80].

Proton therapy is a new treatment for patients with NSCLC, especially for those with early-stage disease and centrally located lesions. The main advantage of proton therapy over other forms of external beam radiation therapy is its lower quantity of scattered radiation [80]. Hata et al. [81] suggested that proton beams might contribute to greater efficacy and lower toxicity in the management of patients with stage I NSCLC and pulmonary fibrosis. The hypothetical efficacy of proton therapy in comparison with SBRT for the treatment of lung cancer in IPF patients needs further investigation. One might predict improved outcomes because, like with wedge resection, less lung is compromised.

Conclusion

Guidelines are well established for the screening, diagnosis and management of lung cancer in patients with a history of smoking, but not for patients with lung cancer associated with pulmonary fibrosis. Prospective studies in patients with fibrosis are needed to learn how to diagnose lung cancer early and treat it more effectively to limit morbidity and mortality. FDG PET-CT scanning may play a role in early diagnosis. Sub-lobar surgical resections, immunotherapy and proton therapy show potential, but further investigation is necessary regarding survival and quality of life for the patients who already have a significant respiratory compromise. Further research is necessary when current treatments add little more than palliative care.

Footnotes

  • Conflict of interest: M.M. Salvatore reports the following relationships outside the submitted work: speaker and Advisory Board fees received from Genentech and Boehringer Ingelheim; and grant funding received from Boehringer Ingelheim and Genentech. M. Padilla reports the following relationships outside the submitted work: speaker fees received from Genentech; and consultancy fees received from Boehringer Ingelheim. The remaining authors have nothing to disclose.

  • Received June 6, 2022.
  • Accepted September 14, 2022.
  • Copyright ©ERS 2023
http://creativecommons.org/licenses/by-nc/4.0/

Breathe articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. Ley B,
    2. Collard HR
    . Epidemiology of idiopathic pulmonary fibrosis. Clin Epidemiol 2013; 5: 483–492. doi:10.2147/CLEP.S54815
    OpenUrlCrossRefPubMed
  2. ↵
    1. Stella GM,
    2. D'Agnano V,
    3. Piloni D, et al.
    The oncogenic landscape of the idiopathic pulmonary fibrosis: a narrative review. Transl Lung Cancer Res 2022; 11: 472–496. doi:10.21037/tlcr-21-880
    OpenUrl
  3. ↵
    1. Jung HI,
    2. Park JS,
    3. Lee MY, et al.
    Prevalence of lung cancer in patients with interstitial lung disease is higher than in those with chronic obstructive pulmonary disease. Medicine 2018; 97: e0071. doi:10.1097/MD.0000000000010071
    OpenUrlPubMed
  4. ↵
    1. Ozawa Y,
    2. Suda T,
    3. Naito T, et al.
    Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology 2009; 14: 723–728. doi:10.1111/j.1440-1843.2009.01547.x
    OpenUrlCrossRefPubMed
  5. ↵
    1. Yoon JH,
    2. Nouraie M,
    3. Chen X, et al.
    Characteristics of lung cancer among patients with idiopathic pulmonary fibrosis and interstitial lung disease – analysis of institutional and population data. Respir Res 2018; 19: 195. doi:10.1186/s12931-018-0899-4
    OpenUrlPubMed
  6. ↵
    1. Tzouvelekis A,
    2. Karampitsakos T,
    3. Gomatou G, et al.
    Lung cancer in patients with idiopathic pulmonary fibrosis. A retrospective multicenter study in Greece. Pulm Pharmacol Ther 2020; 60: 101880. doi:10.1016/j.pupt.2019.101880
    OpenUrlPubMed
  7. ↵
    1. Tzouvelekis A,
    2. Gomatou G,
    3. Bouros E, et al.
    Common pathogenic mechanisms between idiopathic pulmonary fibrosis and lung cancer. Chest 2019; 156: 383–391. doi:10.1016/j.chest.2019.04.114
    OpenUrlCrossRefPubMed
  8. ↵
    1. Choi WI,
    2. Park SH,
    3. Park BJ, et al.
    Interstitial lung disease and lung cancer development: a 5-year nationwide population-based study. Cancer Res Treat 2018; 50: 374–381. doi:10.4143/crt.2017.119
    OpenUrl
  9. ↵
    1. Naccache JM,
    2. Gibiot Q,
    3. Monnet I, et al.
    Lung cancer and interstitial lung disease: a literature review. J Thorac Dis 2018; 10: 3829–3844. doi:10.21037/jtd.2018.05.75
    OpenUrlCrossRef
    1. Kato E,
    2. Takayanagi N,
    3. Takaku Y, et al.
    Incidence and predictive factors of lung cancer in patients with idiopathic pulmonary fibrosis. ERJ Open Res 2018; 4: 00111-2016. doi:10.1183/23120541.00111-2016
    OpenUrlAbstract/FREE Full Text
    1. Nagai A,
    2. Chiyotani A,
    3. Nakadate T, et al.
    Lung cancer in patients with idiopathic pulmonary fibrosis. Tohoku J Exp Med 1992; 167: 231–237. doi:10.1620/tjem.167.231
    OpenUrlCrossRefPubMed
    1. JafariNezhad A,
    2. YektaKooshali MH
    . Lung cancer in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. PLoS One 2018; 13: e0202360. doi:10.1371/journal.pone.0202360
    OpenUrlPubMed
  10. ↵
    1. Matsushita H,
    2. Tanaka S,
    3. Saiki Y, et al.
    Lung cancer associated with usual interstitial pneumonia. Pathol Int 1995; 45: 925–932. doi:10.1111/j.1440-1827.1995.tb03417.x
    OpenUrlCrossRefPubMed
  11. ↵
    1. Whittaker Brown SA,
    2. Padilla M,
    3. Mhango G, et al.
    Interstitial lung abnormalities and lung cancer risk in the National Lung Screening Trial. Chest 2019; 156: 1195–1203. doi:10.1016/j.chest.2019.06.041
    OpenUrlCrossRefPubMed
  12. ↵
    1. Whittaker Brown SA,
    2. Dobelle M,
    3. Padilla M, et al.
    Idiopathic pulmonary fibrosis and lung cancer. A systematic review and meta-analysis. Ann Am Thorac Soc 2019; 16: 1041–1051. doi:10.1513/AnnalsATS.201807-481OC
    OpenUrlCrossRefPubMed
  13. ↵
    1. Tomassetti S,
    2. Gurioli C,
    3. Ryu JH, et al.
    The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest 2015; 147: 157–164. doi:10.1378/chest.14-0359
    OpenUrlCrossRefPubMed
  14. ↵
    1. Giopanou I,
    2. Arendt KAM,
    3. Stathopoulos GT
    . Lung carcinogenesis and fibrosis taken together: just coincidence? Curr Opin Pulm Med 2017; 23: 290–297. doi:10.1097/MCP.0000000000000390
    OpenUrl
  15. ↵
    1. Brett S,
    2. Irusen EM,
    3. Koegelenberg CFN
    . Pulmonary scarring and its relation to primary lung cancer. Afr J Thorac Crit Care Med 2020; 26: 8–11. doi:10.7196/ajtccm.2020.v26i1.050
    OpenUrl
  16. ↵
    1. Zhang Q,
    2. Yu N,
    3. Lee C
    . Mysteries of TGF-β paradox in benign and malignant cells. Front Oncol 2014; 4: 94. doi:10.3389/fonc.2014.00094
    OpenUrlPubMed
  17. ↵
    1. Principe DR,
    2. Doll JA,
    3. Bauer J, et al.
    TGF-β: duality of function between tumor prevention and carcinogenesis. J Natl Cancer Inst 2014; 106: djt369. doi:10.1093/jnci/djt369
    OpenUrlCrossRefPubMed
  18. ↵
    1. Wlodarchak N,
    2. Xing Y
    . PP2A as a master regulator of the cell cycle. Crit Rev Biochem Mol Biol 2016; 51: 162–184. doi:10.3109/10409238.2016.1143913
    OpenUrlCrossRefPubMed
  19. ↵
    1. Ruwanpura SM,
    2. Thomas BJ,
    3. Bardin PG
    . Pirfenidone: molecular mechanisms and potential clinical applications in lung disease. Am J Respir Cell Mol Biol 2020; 62: 413–422. doi:10.1165/rcmb.2019-0328TR
    OpenUrlCrossRefPubMed
  20. ↵
    1. Stuart BD,
    2. Lee JS,
    3. Kozlitina J, et al.
    Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation. Lancet Respir Med 2014; 2: 557–565. doi:10.1016/S2213-2600(14)70124-9
    OpenUrl
  21. ↵
    1. Guo X,
    2. Sunil C,
    3. Adeyanju O, et al.
    PD-L1 mediates lung fibroblast to myofibroblast transition through Smad3 and β-catenin signaling pathways. Sci Rep 2022; 12: 3053. doi:10.1038/s41598-022-07044-3
    OpenUrlCrossRef
  22. ↵
    1. Patsoukis N,
    2. Wang Q,
    3. Strauss L, et al.
    Revisiting the PD-1 pathway. Sci Adv 2020; 6: eabd2712. doi:10.1126/sciadv.abd2712
    OpenUrlFREE Full Text
  23. ↵
    1. Saito A,
    2. Horie M,
    3. Micke P, et al.
    The role of TGF-β signaling in lung cancer associated with idiopathic pulmonary fibrosis. Int J Mol Sci 2018; 19: 3611. doi:10.3390/ijms19113611
    OpenUrl
  24. ↵
    1. Trusolino L,
    2. Bertotti A,
    3. Comoglio PM
    . MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010; 11: 834–848. doi:10.1038/nrm3012
    OpenUrlCrossRefPubMed
  25. ↵
    1. Ariyawutyakorn W,
    2. Saichaemchan S,
    3. Garcia MV
    . Understanding and targeting MET signaling in solid tumors – are we there yet? J Cancer 2016; 7: 633–649. doi:10.7150/jca.12663
    OpenUrl
  26. ↵
    1. Organ SL,
    2. Tsao MS
    . An overview of the c-MET signaling pathway. Ther Adv Med Oncol 2011; 3: Suppl. 1, S7–S19. doi:10.1177/1758834011422556
    OpenUrlCrossRefPubMed
  27. ↵
    1. Stella GM,
    2. Gentile A,
    3. Baderacchi A, et al.
    Ockham's razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancer. J Transl Med 2016; 14: 256. doi:10.1186/s12967-016-1008-4
    OpenUrl
  28. ↵
    1. Kinoshita T,
    2. Goto T
    . Molecular mechanisms of pulmonary fibrogenesis and its progression to lung cancer: a review. Int J Mol Sci 2019; 20: 1461. doi:10.3390/ijms20061461
    OpenUrl
  29. ↵
    1. Cooper J,
    2. Giancotti FG
    . Integrin signaling in cancer: mechanotransduction, stemness, epithelial plasticity, and therapeutic resistance. Cancer Cell 2019; 35: 347–367. doi:10.1016/j.ccell.2019.01.007
    OpenUrlCrossRefPubMed
  30. ↵
    1. Burgess JK,
    2. Mauad T,
    3. Tjin G, et al.
    The extracellular matrix – the under-recognized element in lung disease? J Pathol 2016; 240: 397–409. doi:10.1002/path.4808
    OpenUrlCrossRef
  31. ↵
    1. Lo CM,
    2. Wang HB,
    3. Dembo M, et al.
    Cell movement is guided by the rigidity of the substrate. Biophys J 2000; 79: 144–152. doi:10.1016/S0006-3495(00)76279-5
    OpenUrlCrossRefPubMed
  32. ↵
    1. Schwager SC,
    2. Taufalele PV,
    3. Reinhart-King CA
    . Cell–cell mechanical communication in cancer. Cell Mol Bioeng 2019; 12: 1–14. doi:10.1007/s12195-018-00564-x
    OpenUrlCrossRefPubMed
  33. ↵
    1. Nissen NI,
    2. Karsdal M,
    3. Willumsen N
    . Collagens and cancer associated fibroblasts in the reactive stroma and its relation to cancer biology. J Exp Clin Cancer Res 2019; 38: 115. doi:10.1186/s13046-019-1110-6
    OpenUrlCrossRefPubMed
  34. ↵
    1. Hoffmann EJ,
    2. Ponik SM
    . Biomechanical contributions to macrophage activation in the tumor microenvironment. Front Oncol 2020; 10: 787. doi:10.3389/fonc.2020.00787
    OpenUrl
  35. ↵
    1. Brabletz T,
    2. Kalluri R,
    3. Nieto MA, et al.
    EMT in cancer. Nat Rev Cancer 2018; 18: 128–134. doi:10.1038/nrc.2017.118
    OpenUrlCrossRefPubMed
  36. ↵
    1. Meyer EC,
    2. Liebow AA
    . Relationship of interstitial pneumonia honeycombing and atypical epithelial proliferation to cancer of the lung. Cancer 1965; 18: 322–351. doi:10.1002/1097-0142(196503)18:3<322::AID-CNCR2820180310>3.0.CO;2-J
    OpenUrlCrossRefPubMed
  37. ↵
    1. Ballester B,
    2. Milara J,
    3. Cortijo J
    . Idiopathic pulmonary fibrosis and lung cancer: mechanisms and molecular targets. Int J Mol Sci 2019; 20: 593. doi:10.3390/ijms20030593
    OpenUrl
  38. ↵
    1. Königshoff M
    . Lung cancer in pulmonary fibrosis: tales of epithelial cell plasticity. Respiration 2011; 81: 353–358. doi:10.1159/000326299
    OpenUrlCrossRefPubMed
  39. ↵
    1. Karampitsakos T,
    2. Tzilas V,
    3. Tringidou R, et al.
    Lung cancer in patients with idiopathic pulmonary fibrosis. Pulm Pharmacol Ther 2017; 45: 1–10. doi:10.1016/j.pupt.2017.03.016
    OpenUrlCrossRefPubMed
  40. ↵
    1. Horowitz JC,
    2. Osterholzer JJ,
    3. Marazioti A, et al.
    “Scar-cinoma”: viewing the fibrotic lung mesenchymal cell in the context of cancer biology. Eur Respir J 2016; 47: 1842–1854. doi:10.1183/13993003.01201-2015
    OpenUrlAbstract/FREE Full Text
  41. ↵
    1. Liberti MV,
    2. Locasale JW
    . The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci 2016; 41: 211–218. doi:10.1016/j.tibs.2015.12.001
    OpenUrlCrossRefPubMed
  42. ↵
    1. Berman JJ,
    2. Albores-Saavedra J,
    3. Bostwick D, et al.
    Precancer: a conceptual working definition – results of a Consensus Conference. Cancer Detect Prev 2006; 30: 387–394. doi:10.1016/j.cdp.2006.09.002
    OpenUrlCrossRefPubMed
  43. ↵
    1. Houston KA,
    2. Henley SJ,
    3. Li J, et al.
    Patterns in lung cancer incidence rates and trends by histologic type in the United States, 2004–2009. Lung Cancer 2014; 86: 22–28. doi:10.1016/j.lungcan.2014.08.001
    OpenUrlCrossRefPubMed
  44. ↵
    1. Zieliński M,
    2. Sitek P,
    3. Ziora D
    . Idiopathic pulmonary fibrosis coexisting with lung cancer – a review. Adv Respir Med 2018; 86: 319–326. doi:10.5603/ARM.a2018.0052
    OpenUrl
    1. Vancheri C
    . Idiopathic pulmonary fibrosis and cancer: do they really look similar? BMC Med 2015; 13: 220. doi:10.1186/s12916-015-0478-1
    OpenUrlCrossRefPubMed
    1. Antoniou KM,
    2. Tomassetti S,
    3. Tsitoura E, et al.
    Idiopathic pulmonary fibrosis and lung cancer: a clinical and pathogenesis update. Curr Opin Pulm Med 2015; 21: 626–633. doi:10.1097/MCP.0000000000000217
    OpenUrlCrossRefPubMed
  45. ↵
    1. Samet JM,
    2. Avila-Tang E,
    3. Boffetta P, et al.
    Lung cancer in never smokers: clinical epidemiology and environmental risk factors. Clin Cancer Res 2009; 15: 5626–5645. doi:10.1158/1078-0432.CCR-09-0376
    OpenUrlAbstract/FREE Full Text
  46. ↵
    1. Kishi K,
    2. Homma S,
    3. Kurosaki A, et al.
    High-resolution computed tomography findings of lung cancer associated with idiopathic pulmonary fibrosis. J Comput Assist Tomogr 2006; 30: 95–99. doi:10.1097/01.rct.0000188650.66527.d2
    OpenUrlCrossRefPubMed
  47. ↵
    1. Lee T,
    2. Park JY,
    3. Lee HY, et al.
    Lung cancer in patients with idiopathic pulmonary fibrosis: clinical characteristics and impact on survival. Respir Med 2014; 108: 1549–1555. doi:10.1016/j.rmed.2014.07.020
    OpenUrlCrossRefPubMed
  48. ↵
    1. Khan KA,
    2. Kennedy MP,
    3. Moore E, et al.
    Radiological characteristics, histological features and clinical outcomes of lung cancer patients with coexistent idiopathic pulmonary fibrosis. Lung 2015; 193: 71–77. doi:10.1007/s00408-014-9664-8
    OpenUrlPubMed
  49. ↵
    1. Kalla IS
    . Scar carcinoma – a real entity or a historical ‘histological curiosity’? Afr J Thorac Crit Care Med 2020; 26: 4. doi:10.7196/AJTCCM.2020.v26i1.066
    OpenUrl
  50. ↵
    1. Gulati S,
    2. Mulshine JL
    . Lung cancer screening guidelines: common ground and differences. Transl Lung Cancer Res 2014; 3: 131–138. doi:10.3978/j.issn.2218-6751.2014.06.12
    OpenUrl
  51. ↵
    1. Tzouvelekis A,
    2. Spagnolo P,
    3. Bonella F, et al.
    Patients with IPF and lung cancer: diagnosis and management. Lancet Respir Med 2018; 6: 86–88. doi:10.1016/S2213-2600(17)30478-2
    OpenUrl
  52. ↵
    1. Shin YJ,
    2. Yun G,
    3. Yoon SH, et al.
    Accuracy and complications of percutaneous transthoracic needle lung biopsy for the diagnosis of malignancy in patients with idiopathic pulmonary fibrosis. Eur Radiol 2021; 31: 9000–9011. doi:10.1007/s00330-021-08038-x
    OpenUrl
  53. ↵
    1. Yamazaki R,
    2. Nishiyama O,
    3. Gose K, et al.
    Pneumothorax in patients with idiopathic pulmonary fibrosis: a real-world experience. BMC Pulm Med 2021; 21: 5. doi:10.1186/s12890-020-01370-w
    OpenUrl
  54. ↵
    1. Iyoda A,
    2. Azuma Y,
    3. Sakamoto S, et al.
    Surgical treatment for patients with idiopathic pulmonary fibrosis and lung cancer: postoperative acute exacerbation of idiopathic pulmonary fibrosis and outcomes. Surg Today 2022; 52: 736–744. doi:10.1007/s00595-021-02343-0
    OpenUrl
  55. ↵
    1. Bargagli E,
    2. Bonti V,
    3. Ferrari K, et al.
    Lung cancer in patients with severe idiopathic pulmonary fibrosis: critical aspects. In Vivo 2017; 31: 773–777. doi:10.21873/invivo.11130
    OpenUrlAbstract/FREE Full Text
  56. ↵
    1. Goto T,
    2. Maeshima A,
    3. Oyamada Y, et al.
    Idiopathic pulmonary fibrosis as a prognostic factor in non-small cell lung cancer. Int J Clin Oncol 2014; 19: 266–273. doi:10.1007/s10147-013-0566-1
    OpenUrlCrossRefPubMed
  57. ↵
    1. Saito Y,
    2. Kawai Y,
    3. Takahashi N, et al.
    Survival after surgery for pathologic stage IA non-small cell lung cancer associated with idiopathic pulmonary fibrosis. Ann Thorac Surg 2011; 92: 1812–1817. doi:10.1016/j.athoracsur.2011.06.055
    OpenUrlCrossRefPubMed
  58. ↵
    1. Goto T
    . Measuring surgery outcomes of lung cancer patients with concomitant pulmonary fibrosis: a review of the literature. Cancers 2018; 10: 223. doi:10.3390/cancers10070223
    OpenUrl
  59. ↵
    1. Iwata T,
    2. Yoshida S,
    3. Nagato K, et al.
    Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis. Surg Today 2015; 45: 1263–1270. doi:10.1007/s00595-014-1071-5
    OpenUrl
  60. ↵
    1. Hui R,
    2. Garon EB,
    3. Goldman JW, et al.
    Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. Ann Oncol 2017; 28: 874–881. doi:10.1093/annonc/mdx008
    OpenUrlCrossRefPubMed
    1. Afzal MZ,
    2. Dragnev KH,
    3. Shirai K
    . An extended overall survival analysis of pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced non-squamous non-small cell lung cancer. Ann Transl Med 2019; 7: Suppl. 1, S53. doi:10.21037/atm.2019.03.09
    OpenUrl
  61. ↵
    1. Paz-Ares L,
    2. Luft A,
    3. Vicente D, et al.
    Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer. N Engl J Med 2018; 379: 2040–2051. doi:10.1056/nejmoa1810865
    OpenUrlCrossRefPubMed
  62. ↵
    1. Ide M,
    2. Tanaka K,
    3. Sunami S, et al.
    Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis. Thorac Cancer 2018; 9: 1519–1521. doi:10.1111/1759-7714.12853
    OpenUrl
  63. ↵
    1. Yamaguchi T,
    2. Shimizu J,
    3. Hasegawa T, et al.
    Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: a retrospective analysis. Lung Cancer 2018; 125: 212–217. doi:10.1016/j.lungcan.2018.10.001
    OpenUrlCrossRefPubMed
  64. ↵
    1. Watanabe N,
    2. Taniguchi H,
    3. Kondoh Y, et al.
    Efficacy of chemotherapy for advanced non-small cell lung cancer with idiopathic pulmonary fibrosis. Respiration 2013; 85: 326–331. doi:10.1159/000342046
    OpenUrlCrossRefPubMed
  65. ↵
    1. Minegishi Y,
    2. Sudoh J,
    3. Kuribayasi H, et al.
    The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias. Lung Cancer 2011; 71: 70–74. doi:10.1016/j.lungcan.2010.04.014
    OpenUrlCrossRefPubMed
  66. ↵
    1. Rice LM,
    2. Padilla CM,
    3. McLaughlin SR, et al.
    Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J Clin Invest 2015; 125: 2795–2807. doi:10.1172/JCI77958
    OpenUrlCrossRefPubMed
  67. ↵
    1. Yamamoto Y,
    2. Yano Y,
    3. Kuge T, et al.
    Safety and effectiveness of pirfenidone combined with carboplatin-based chemotherapy in patients with idiopathic pulmonary fibrosis and non-small cell lung cancer: a retrospective cohort study. Thorac Cancer 2020; 11: 3317–3325. doi:10.1111/1759-7714.13675
    OpenUrl
  68. ↵
    1. Fujiwara A,
    2. Funaki S,
    3. Fukui E, et al.
    Effects of pirfenidone targeting the tumor microenvironment and tumor-stroma interaction as a novel treatment for non-small cell lung cancer. Sci Rep 2020; 10: 10900. doi:10.1038/s41598-020-67904-8
    OpenUrl
  69. ↵
    1. Espinosa Bosch M,
    2. Asensi Diez R,
    3. García Agudo S, et al.
    Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer; GENESIS-SEFH drug evaluation report. Farm Hosp 2016; 40: 316–327. doi:10.7399/fh.2016.40.4.10455
    OpenUrl
  70. ↵
    1. Appel S,
    2. Lawrence YR,
    3. Goldstein J, et al.
    Stereotactic ablative body radiation for stage I lung cancer in Israel: a retrospective single-center report. Isr Med Assoc J 2017; 19: 39–43.
    OpenUrl
    1. Lischalk JW,
    2. Woo SM,
    3. Kataria S, et al.
    Long-term outcomes of stereotactic body radiation therapy (SBRT) with fiducial tracking for inoperable stage I non-small cell lung cancer (NSCLC). J Radiat Oncol 2016; 5: 379–387. doi:10.1007/s13566-016-0273-4
    OpenUrl
  71. ↵
    1. Ettinger DS,
    2. Wood DE,
    3. Aggarwal C, et al.
    NCCN guidelines insights: non-small cell lung cancer, version 1.2020. J Natl Compr Canc Netw 2019; 17: 1464–1472. doi:10.6004/jnccn.2019.0059
    OpenUrlCrossRefPubMed
  72. ↵
    1. Yamashita H,
    2. Kobayashi-Shibata S,
    3. Terahara A, et al.
    Prescreening based on the presence of CT-scan abnormalities and biomarkers (KL-6 and SP-D) may reduce severe radiation pneumonitis after stereotactic radiotherapy. Radiat Oncol 2010; 5: 32. doi:10.1186/1748-717X-5-32
    OpenUrlCrossRefPubMed
  73. ↵
    1. Kim H,
    2. Pyo H,
    3. Noh JM, et al.
    Preliminary result of definitive radiotherapy in patients with non-small cell lung cancer who have underlying idiopathic pulmonary fibrosis: comparison between X-ray and proton therapy. Radiat Oncol 2019; 14: 19. doi:10.1186/s13014-019-1221-4
    OpenUrl
  74. ↵
    1. Hata M,
    2. Tokuuye K,
    3. Kagei K, et al.
    Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: preliminary results of a phase I/II clinical study. Int J Radiat Oncol Biol Phys 2007; 68: 786–793. doi:10.1016/j.ijrobp.2006.12.063
    OpenUrlPubMed
PreviousNext
Back to top
Vol 18 Issue 4 Table of Contents
Breathe: 18 (4)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Idiopathic pulmonary fibrosis and lung cancer: future directions and challenges
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Idiopathic pulmonary fibrosis and lung cancer: future directions and challenges
Ahmad Abu Qubo, Jamil Numan, Juan Snijder, Maria Padilla, John H.M. Austin, Kathleen M. Capaccione, Monica Pernia, Jean Bustamante, Timothy O'Connor, Mary M. Salvatore
Breathe Dec 2022, 18 (4) 220147; DOI: 10.1183/20734735.0147-2022

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Idiopathic pulmonary fibrosis and lung cancer: future directions and challenges
Ahmad Abu Qubo, Jamil Numan, Juan Snijder, Maria Padilla, John H.M. Austin, Kathleen M. Capaccione, Monica Pernia, Jean Bustamante, Timothy O'Connor, Mary M. Salvatore
Breathe Dec 2022, 18 (4) 220147; DOI: 10.1183/20734735.0147-2022
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Why does lung cancer occur in pulmonary fibrosis?
    • Is lung fibrosis a precancerous condition?
    • Difference between lung cancers in fibrotic versus non-fibrotic lung
    • Lung cancer screening in patients with pulmonary fibrosis
    • Treatment of lung cancer in patients with pulmonary fibrosis
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Interstitial and orphan lung disease
  • Lung cancer
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Diagnosis and management of PH related to chronic respiratory disease
  • Pulmonary renal syndrome: a clinical review
Show more Reviews

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About Breathe

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Intructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 1810-6838
Online ISSN: 2073-4735

Copyright © 2023 by the European Respiratory Society